Foghorn Therapeutics Reports Increased Collaboration Revenue and Reduced Operating Losses in Q2 2026

Foghorn Therapeutics Inc. reported its financial results for the second quarter of 2026, revealing a significant increase in collaboration revenue and a reduction in operating losses compared to the same period last year. The company generated $16.1 million in collaboration revenue for the three months ended June 30, 2026, up from $7.6 million in the same quarter of 2025. For the first half of 2026, collaboration revenue reached $19.3 million, compared to $13.5 million in the prior year. This increase is attributed to a $14.2 million cumulative catch-up adjustment related to the Lilly Collaboration Agreement, reflecting updated future costs.

Operating expenses for the second quarter decreased to $24.9 million from $28.7 million in the prior year, driven by lower research and development costs, which fell to $18.5 million from $21.8 million. General and administrative expenses also declined to $6.4 million from $6.9 million. The net loss for the quarter was $7.2 million, a notable improvement from the $17.9 million loss reported in the same quarter of 2025. For the first half of 2026, the net loss was $27.1 million, down from $36.8 million in the previous year.

Foghorn's operational developments include the transition of its selective SMARCA2 inhibitor, FHD-909, into development activities led by Eli Lilly, which began in the third quarter of 2023. The collaboration with Lilly, initiated in December 2021, includes co-development and co-commercialization of several oncology programs, with Foghorn leading early research activities. As of June 30, 2026, the company had $229.8 million in deferred revenue related to this collaboration, expected to be recognized over the coming years as research activities progress.

The company’s financial position remains stable, with cash, cash equivalents, and marketable securities totaling $167.6 million as of June 30, 2026. This figure reflects a decrease from $198.1 million at the end of 2025, primarily due to cash used in operating activities and investments in marketable securities. Foghorn anticipates that its current cash reserves will be sufficient to fund operations for at least the next 12 months, although it will need to secure additional funding through equity offerings or collaborations to support ongoing and future development activities.

Looking ahead, Foghorn expects to continue incurring significant operating losses as it advances its clinical programs and expands its research pipeline. The company is focused on developing its Gene Traffic Control platform and aims to initiate further clinical trials for its product candidates. Management has indicated that while they are optimistic about future revenue generation from collaborations and potential product sales, the path to profitability remains uncertain and will depend on the successful development and commercialization of their therapeutic candidates.